4//SEC Filing
SYNAGEVA BIOPHARMA CORP 4
Accession 0001209191-15-055577
CIK 0000911326operating
Filed
Jun 22, 8:00 PM ET
Accepted
Jun 23, 10:35 AM ET
Size
15.8 KB
Accession
0001209191-15-055577
Insider Transaction Report
Form 4
TISCH THOMAS J
10% Owner
Transactions
- Disposition to Issuer
Common Stock
2015-06-22−373,560→ 0 total(indirect: By Trust) - Disposition to Issuer
Common Stock
2015-06-22−378,435→ 0 total - Disposition to Issuer
Stock Options (Right to Buy)
2015-06-22−7,500→ 0 totalExercise: $80.35Exp: 2024-06-04→ Common Stock (7,500 underlying) - Disposition to Issuer
Stock Options (Right to Buy)
2015-06-22−7,500→ 0 totalExercise: $40.32Exp: 2023-06-06→ Common Stock (7,500 underlying) - Disposition to Issuer
Stock Options (Right to Buy)
2015-06-22−15,000→ 0 totalExercise: $40.74Exp: 2022-06-27→ Common Stock (15,000 underlying)
Footnotes (4)
- [F1]These shares are being disposed of in connection with a merger following the completion of an exchange offer by Pulsar Merger Sub Inc., a Delaware corporation ("Purchaser") and Alexion Pharmaceuticals, Inc., a Delaware corporation ("Parent") to purchase all of the issued and outstanding shares of common stock of Synageva, pursuant to an Agreement and Plan of Reorganization (the "Merger Agreement"), dated May 5, 2015, among Parent, Purchaser, Merger Sub, Galaxy Merger Sub LLC and Synageva. Each outstanding share of Synageva common stock was automatically cancelled and converted into the right to receive (a) $115.00 in cash; and (b) 0.6581 of a share of Parent's common stock, without interest, but subject to any required withholding of taxes (the "Transaction Consideration").
- [F2]Pursuant to the Merger Agreement, these options, which vest 25% on 07/06/2013 and 1/36 of the remainder of the shares vest and become exercisable monthly thereafter, accelerated, became fully vested and were cancelled pursuant to the Merger Agreement in exchange for an amount in cash and shares of Alexion common stock equal to (i) the Transaction Consideration multiplied by (ii) a number of shares of Synageva common stock equal to (1) $230.00 minus the per share exercise price, divided by (2) $230.00, with the cash portion of such amount rounded down to the nearest cent and with the portion of such amount payable in shares of Parent common stock rounded down to the nearest one thousandth of a share.
- [F3]Pursuant to the Merger Agreement, these options, which vest 25% on 07/27/2012 and 1/36 of the remainder of the shares vest and become exercisable monthly thereafter, accelerated, became fully vested and were cancelled pursuant to the Merger Agreement in exchange for an amount in cash and shares of Alexion common stock equal to (i) the Transaction Consideration multiplied by (ii) a number of shares of Synageva common stock equal to (1) $230.00 minus the per share exercise price, divided by (2) $230.00, with the cash portion of such amount rounded down to the nearest cent and with the portion of such amount payable in shares of Parent common stock rounded down to the nearest one thousandth of a share.
- [F4]Pursuant to the Merger Agreement, these options, which vest 25% on 07/04/2014 and 1/36 of the remainder of the shares vest and become exercisable monthly thereafter, accelerated, became fully vested and were cancelled pursuant to the Merger Agreement in exchange for an amount in cash and shares of Alexion common stock equal to (i) the Transaction Consideration multiplied by (ii) a number of shares of Synageva common stock equal to (1) $230.00 minus the per share exercise price, divided by (2) $230.00, with the cash portion of such amount rounded down to the nearest cent and with the portion of such amount payable in shares of Parent common stock rounded down to the nearest one thousandth of a share.
Documents
Issuer
SYNAGEVA BIOPHARMA CORP
CIK 0000911326
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0000911326
Filing Metadata
- Form type
- 4
- Filed
- Jun 22, 8:00 PM ET
- Accepted
- Jun 23, 10:35 AM ET
- Size
- 15.8 KB